Special Instructions

Test orders must include an attestation that the provider has the patient's informed consent for genetic testing. In family testing scenarios, where known mutations are involved, the result report of the initial patient (index case) should be provided if not tested at LabCorp. Other family members are subsequently assessed for specific mutations identified in the index case.

Limitations

This testing method does not accurately detect mosaic variants, large deletions, large duplications, inversions, rearrangements or deep intronic variants. There may be issues with allele dropout, and it may not determine the exact numbers of T/A or microsatellite repeats, nor can it confirm if two heterozygous variants occur on the same or different chromosome copies. It has been developed by Labcorp, with performance characteristics determined internally, and it is not cleared or approved by the FDA.

Biomarkers

LOINC Codes

Result Turnaround Time

Related Documents